XLO - Cancer Focused Micro-Cap Xilio Therapeutics Stock Doubles In One Session - Here's Why | Benzinga
Xilio Therapeutics Inc (NASDAQ:XLO) shares are surging as the company announced an exclusive license agreement with Gilead Sciences Inc (NASDAQ:GILD) to develop and commercialize Xilio’s Phase 1 tumor-activated IL-12 program, XTX301.
Xilio Therapeutics is using its proprietary tumor-activation platform to build a pipeline of novel, tumor-activated molecules, including antibodies, cytokines, bispecifics, and cell engagers, which are designed to optimize the therapeutic index and localize anti-tumor activity within the tumor microenvironment.
XTX301 is currently being evaluated in a Phase 1 dose-escalation trial in patients with advanced solid tumors.
“Gilead’s confidence in our tumor-activated technology, combined with their deep expertise in developing and commercializing novel immuno-oncology products, will enable us to accelerate and expand the development of XTX301, ...